アジア太平洋地域のブランドジェネリック市場規模、トレンド、成長レポート2032

アジア太平洋地域におけるブランドジェネリック医薬品市場の規模、シェア、トレンド分析レポート

Market Size in USD Billion

CAGR : 4.80 %

USD 95.35 Billion USD 137.97 Billion 2024 2032

予測期間	2025 –2032
市場規模（基準年）	USD 95.35 Billion
Market Size (Forecast Year)	USD 137.97 Billion
CAGR	4.80 %
Major Markets Players	Teva Pharmaceutical Industries Ltd. Viatris Inc. Sandoz Group AG Dr. Reddy’s Laboratories Ltd. Sun Pharmaceutical Industries Ltd.

アジア太平洋地域におけるブランドジェネリック医薬品市場の細分化：薬物クラス別（降圧剤、ホルモン剤、代謝拮抗剤、脂質低下薬、抗てんかん剤、アルキル化剤、抗うつ剤、抗精神病薬、その他）、用途別（心血管疾患、疼痛管理・抗炎症剤、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他）、投与経路別（経口、注射、局所投与、その他）、製品タイプ別（付加価値ブランドジェネリック医薬品、商品名ジェネリック医薬品）、患者層別（成人、高齢者、小児）、エンドユーザー別（病院、診療所、在宅ケア、学術研究機関、その他）、流通チャネル別（小売薬局、病院薬局、直接販売、その他） - 2032年までの業界動向と予測

アジア太平洋地域のブランドジェネリック医薬品市場規模

アジア太平洋地域のブランドジェネリック医薬品市場は2024年に953.5億米ドルと評価され、 2032年までに1,379.7億米ドルに達すると予想されています。
2025年から2032年の予測期間中、市場は4.8％のCAGRで成長すると予想されます。これは主に、医療費の増加、慢性疾患の罹患率の上昇、先進国と新興国市場の両方における手頃な価格で高品質の医薬品の需要に牽引されています。
この成長は、先発医薬品の特許満了、費用対効果の高い治療を支援する政府の政策、新興国における医療アクセスの拡大、デジタルヘルスおよびeファーマシーチャネルの普及拡大によってさらに促進されています。医薬品処方の継続的な革新、患者アドヒアランス戦略の改善、大手製薬会社によるブランドジェネリック医薬品ポートフォリオの拡大も、世界的な市場拡大を加速させると予想されます。

アジア太平洋地域のブランドジェネリック医薬品市場分析

アジア太平洋地域のブランドジェネリック医薬品市場は、ジェネリック医薬品の手頃な価格とブランド認知度を兼ね備えた、費用対効果が高く高品質な医薬品への需要の高まりに牽引され、力強い成長を遂げています。ブランドジェネリック医薬品は、患者の服薬アドヒアランスの向上、必須医薬品へのアクセス拡大、そして新興市場と先進市場の両方において製薬会社への収益機会の提供において重要な役割を果たしています。市場は、国による規制の違い、価格圧力、そしてブランドロイヤルティを維持するための継続的なイノベーションの必要性といった課題に直面しています。
慢性疾患管理、腫瘍学、心血管疾患、感染症治療の各分野が主要な成長ドライバーとなっています。新興国における非感染性疾患の罹患率の上昇、医療意識の高まり、そして医療へのアクセス拡大は、ブランドジェネリック医薬品の需要を押し上げています。さらに、バイオシミラーやスペシャリティジェネリック医薬品の普及拡大は、有効性と安全性を維持しながら、高価な先発医薬品の代替品を提供することで、市場のダイナミクスを形成しています。製薬会社は、マーケティング戦略、患者教育、戦略的パートナーシップを活用し、ブランドジェネリック医薬品の普及を促進しています。
この地域の確立されたジェネリック医薬品製造能力、有利な政府政策、医療費の増加により、中国は市場を支配しており、インドと日本に先導されて最も急速に成長している国でもあります。
降圧剤分野は、簡便な投与量、費用対効果、および治療領域全体にわたる幅広い適用性に対する患者の好みにより、市場シェアの 25.55% を占めて市場を支配すると予想されています。

レポートの範囲とアジア太平洋地域のブランドジェネリック医薬品市場のセグメンテーション

属性	アジア太平洋地域のブランドジェネリック医薬品主要市場インサイト
対象セグメント	薬剤クラス別：降圧剤、ホルモン剤、代謝拮抗剤、脂質低下剤、抗てんかん剤、アルキル化剤、抗うつ剤、抗精神病薬、その他用途別：心血管疾患、疼痛管理および抗炎症、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他投与経路：経口、注射、局所投与、その他製品タイプ別:付加価値ブランドジェネリック、商品名ジェネリック患者属性別：成人、高齢者、小児エンドユーザー別:病院、診療所、在宅ケア、学術研究機関、その他流通チャネル別：小売薬局、病院薬局、直接販売、その他
対象国	アジア太平洋中国日本インド韓国オーストラリアシンガポール台湾ベトナムフィリピンタイマレーシアインドネシアニュージーランドその他のアジア太平洋地域
主要な市場プレーヤー	テバ製薬工業株式会社（イスラエル） Viatris Inc.（中国）サンドスグループAG（スイス） Dr. Reddy's Laboratories Ltd.（インド）サン・ファーマシューティカル・インダストリーズ（インド）オーロビンドファーマ（インド）シプラ・ファーマシューティカルズ（インド）フレゼニウス・カビ（ドイツ）アボット（中国）グレンマーク・ファーマシューティカルズ（インド）ヒクマ・ファーマシューティカルズPLC（英国）ルピン・ファーマシューティカルズ（インド）エムキュア・ファーマシューティカルズ（インド）バウシュ・ヘルス・カンパニーズ（カナダ）マンカインドファーマ（インド）ジュビラント・ファーマ（インド）ナトコファーマ（インド）アリスト・ファーマシューティカルズ・プライベート・リミテッド（インド）バイオコン・リミテッド（インド）トレント・ファーマシューティカルズ社（インド）遠藤株式会社（中国）アレンビック・ファーマシューティカルズ・リミテッド（インド） SAGENT Pharmaceuticals（中国）パナセアバイオテック（インド）
市場機会	新興市場におけるブランドジェネリック医薬品の拡大主要医薬品の特許崖専門分野および複合ジェネリック医薬品への進出
付加価値データ情報セット	Data Bridge Market Research がまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、専門家による詳細な分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

アジア太平洋地域のブランドジェネリック医薬品市場動向

「手頃な価格で高品質な医薬品への需要の高まりがアジア太平洋地域のブランドジェネリック医薬品市場の成長を牽引」

医療費の高騰、人口の高齢化、そして慢性疾患や生活習慣病の罹患率の上昇は、アジア太平洋地域において、手頃な価格でありながら高品質な医薬品への需要を高め、ブランドジェネリック医薬品の成長を支えています。ブランドジェネリック医薬品は、有効性と安全性の高水準を維持しながら、先発医薬品に代わる費用対効果の高い代替品を提供することから、先進国市場と新興国市場の両方で不可欠な存在となっています。
政府と医療保険者は、医療費の抑制、治療へのアクセス拡大、患者の服薬遵守の向上を目的として、政策、償還枠組み、ジェネリック医薬品代替プログラムなどを通じて、ブランドジェネリック医薬品の使用を積極的に推進しています。これらの施策は、心血管疾患、糖尿病、腫瘍学、中枢神経系疾患など、複数の治療領域における市場導入を促進しています。
例えば、2024年3月には、中国FDA（食品医薬品局）が糖尿病や高血圧といった需要の高い治療領域において複数の新しいブランドジェネリック製剤を承認しました。これは、ブランド医薬品に代わる費用対効果の高い代替品に対するパイプライン活動と規制当局の支援の増加を示しています。これは、患者と医療制度のニーズに応えて、アジア太平洋地域のブランドジェネリック医薬品市場が継続的に拡大していることを示しています。
新興国、特にアジア太平洋地域とラテンアメリカでは、医療インフラの拡充、中流階級人口の増加、そして治療へのアクセス向上を目指す政府の取り組みにより、ブランドジェネリック医薬品の普及が加速しています。企業はこれらの地域で高まる需要に対応するため、現地生産の拡大、研究開発への投資、流通ネットワークの強化に取り組んでいます。
アジア太平洋地域の医療制度では、手頃な価格、アクセスしやすさ、治療の遵守を重視し続けるため、製造、パッケージング、患者中心の医薬品開発におけるイノベーションを推進しながら持続可能な医療提供を確保する上で、ブランドジェネリック医薬品の役割はますます重要になります。

アジア太平洋地域のブランドジェネリック医薬品市場の動向

ドライバ

「ブロックバスター医薬品の特許切れ」

アジア太平洋地域のブランドジェネリック医薬品市場の拡大を牽引する最も強力な構造的要因の一つは、ブロックバスター医薬品の特許切れです。収益性の高いイノベーター医薬品が独占権を失うと、ジェネリック医薬品メーカーやバイオシミラーメーカーが競合品を投入する機会が生まれ、イノベーター医薬品の市場シェアは低下し、需要はより低コストの代替品へと向かいます。
この「特許の崖」は、下流で連鎖的な影響を引き起こします。製薬会社は略式新薬申請（ANDA）またはバイオシミラー申請を急いで提出し、規制当局は審査を迅速化し、支払者はジェネリック医薬品をますます好むようになり、患者はより手頃な価格のブランドジェネリック医薬品にアクセスできるようになります。
過去10年間、大手医薬品メーカーにおける独占権喪失の波は、ジェネリック医薬品の既存メーカーと新規参入企業に繰り返しチャンスをもたらし、価格動向の再構築、ジェネリック医薬品製造における統合促進、新興市場への地理的拡大の加速につながりました。実際、特許切れによって失われる収益規模は、複雑なジェネリック医薬品やバイオシミラーへの投資を経済的に正当化する要因となることがよくあります。
重要なのは、特許の崖のタイミングと予測可能性により、ジェネリック医薬品企業は、独占権の喪失前に、上市を予測し、開発パイプラインに投資し、提携を結び、規制書類を事前に提出するための戦略的計画の期間が与えられることである。
その結果、ブランドジェネリック医薬品セクターは、大型製品の特許満了と密接に結びついた、競争の原動力となる循環的なフロンティアとなる。

抑制/挑戦

「特許訴訟と知的財産リスク」

特許訴訟と知的財産リスクは、アジア太平洋地域のブランドジェネリック医薬品市場にとって大きな制約となっています。特許紛争の複雑さと長期化は、ジェネリック医薬品の市場参入を遅らせ、市場競争を阻害し、医薬品価格の高止まりにつながる可能性があります。
これらの法廷闘争には、使用方法特許や二次特許など、多層的な特許請求が含まれることが多く、ブランド医薬品の独占期間が当初の特許期限を超えて延長される可能性があります。
さらに、特許侵害訴訟への対応にかかる経済的負担は、ジェネリック医薬品メーカー、特に中小企業の市場参入を阻む要因となっています。特許法の進化と、先発医薬品メーカーによる特許ポートフォリオの戦略的活用は、市場動向をさらに複雑化し、世界的にブランドジェネリック市場が形成される可能性を秘めています。
例えば、2025年10月、エコノミック・タイムズは、ハイデラバードに拠点を置くナトコ・ファーマが、脊髄性筋萎縮症の治療薬リスジプラムに関するスイス製薬会社ロシュとの特許紛争に勝訴したと報じた。
これらの法的および財務的な障壁は、メーカーの収益性と患者が手頃な価格の医薬品にアクセスできることの両方に影響を与えます。全体として、特許訴訟と知的財産リスクは、アジア太平洋地域のブランドジェネリック医薬品市場における競争と成長に影響を与える主要な制約要因であり続けています。

アジア太平洋地域のブランドジェネリック医薬品市場の展望

アジア太平洋地域のブランドジェネリック医薬品市場は、薬物クラス、用途、投与経路、製品タイプ、患者の人口統計、エンドユーザー、流通チャネルに基づいて、7 つの主要なセグメントに分類されています。

• 薬物クラス別

アジア太平洋地域のブランドジェネリック医薬品市場は、薬剤の種類別に、降圧剤、ホルモン剤、代謝拮抗剤、脂質低下薬、抗てんかん薬、アルキル化剤、抗うつ薬、抗精神病薬、その他に分類されています。2025年には、降圧剤セグメントが25.55%の市場シェアを占め、市場を席巻すると予想されています。これは、心血管疾患の有病率の上昇、高血圧管理に対する意識の高まり、そして患者と医療提供者による費用対効果の高いジェネリック医薬品への嗜好の高まりが要因です。

降圧剤分野は、固定用量併用療法の継続的な革新、手頃な価格の医薬品を推進する政府の取り組み、新興経済国における医療へのアクセスの拡大により、降圧剤ブランドジェネリックの採用が総合的に促進され、2025年から2032年の予測期間中に6.8%のCAGRで成長することが予想されています。

• アプリケーション別

用途別に見ると、市場は心血管疾患、疼痛管理・抗炎症、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他に分類されています。2025年には、アジア太平洋地域における心臓関連疾患の有病率の上昇、高齢化人口の増加、そして予防的な心血管ケアへの意識の高まりと、費用対効果の高いブランドジェネリック医薬品の普及により、心血管疾患セグメントが32.08%の市場シェアで市場を牽引すると予想されています。

心臓血管疾患分野は、新興市場の医療制度により必須医薬品へのアクセスが強化され、固定用量併用療法が普及し、継続的な研究開発により心臓血管治療用ブランドジェネリックの有効性と安全性プロファイルが改善されるため、6.0%のCAGRで着実に拡大すると予測されています。

• 投与経路

アジア太平洋地域のブランドジェネリック医薬品市場は、投与経路に基づいて、経口、注射、局所投与、その他に分類されます。2025年には、経口投与の利便性、患者の高いコンプライアンス、経口製剤の広範な入手性、そして他の投与経路に比べて費用対効果が高いことから、経口セグメントが57.61%の市場シェアで市場をリードすると予想されています。

経口セグメントは、長期投薬を必要とする慢性疾患の増加、自己投与療法の嗜好の高まり、バイオアベイラビリティが向上し患者に優しい設計の革新的な経口製剤の継続的な導入に支えられ、予測期間中に4.9%の加速成長が見込まれます。

• 製品タイプ別

製品タイプ別に見ると、市場は付加価値ブランドジェネリックと商品名ジェネリックに分類されます。2025年には、付加価値ブランドジェネリックが、その優れた有効性、安全性プロファイルの改善、患者中心の処方、そして標準ジェネリックに比べて差別化された治療効果の提供能力により、68.18%の市場シェアで市場をリードすると予想されます。

付加価値ブランドジェネリックセグメントは、患者の服薬遵守を改善する処方に対する医療提供者の嗜好の高まり、併用療法の需要の増加、薬物送達技術の継続的な革新、慢性疾患や複雑な疾患の治療における満たされていない医療ニーズへの対応への重点により、重要性が高まり、4.8%のCAGRで成長しています。

• 患者の人口統計別

患者層に基づき、市場は成人、高齢者、小児の3つに分類されます。2025年には、成人層が66.51%の市場シェアを占めると予想されます。これは、成人人口における心血管疾患、糖尿病、高血圧といった慢性疾患や生活習慣病の有病率の高さが、ブランドジェネリック医薬品に対する継続的な需要を牽引しているためです。

成人セグメントは、ヘルスケアに対する意識の高まり、手頃な価格の医薬品へのアクセスの増加、新興経済国における中流階級人口の増加、成人患者の間でより優れた有効性と服薬遵守を提供する付加価値のあるブランドジェネリック医薬品の選好により、年平均成長率4.9%で成長すると予想されています。

• エンドユーザーによる

エンドユーザーに基づいて、市場は病院、診療所、在宅ケア、学術研究機関、その他に分類されます。2025年には、病院セグメントが53.43%の市場シェアで市場を席巻すると予想されます。これは、患者の治療件数の増加、集中治療におけるブランド医薬品や高品質のジェネリック医薬品への需要、そして必須医薬品の安定供給を確保する病院の集中調達慣行などが要因です。

病院セグメントは、病院インフラの拡張、専門病院および多専門病院の増加、慢性疾患および急性疾患による入院の増加、治療成果の向上を目的とした入院患者ケアにおける付加価値のあるブランドジェネリック医薬品の採用増加により、2025年から2032年の間に5.0%という最も高い成長率を記録すると予想されています。

• 流通チャネル別

流通チャネルに基づき、市場は小売薬局、病院薬局、直接入札、その他に分類されます。2025年には、小売薬局セグメントが54.39%の市場シェアで市場を席巻すると予想されます。これは、ブランドジェネリック医薬品が小売店を通じて広く入手可能であること、医薬品への利便性の高いアクセスを求める消費者の嗜好、そして都市部と準都市部の両方で薬局チェーンと独立系ドラッグストアが強く存在感を示していることが要因です。

小売薬局セグメントは、セルフメディケーションの傾向の増加、費用対効果の高いブランドジェネリック医薬品の認知度の高まり、薬局ネットワークの拡大、小売チャネルを通じた必須医薬品への手頃な価格でのアクセスを支援する政府の取り組みにより、2025年から2032年の間に4.9％という最も高い成長を記録すると予想されています。

アジア太平洋地域のブランドジェネリック医薬品市場 – 地域分析

手頃な価格でありながら高品質の医薬品に対する強い需要と、地域全体での医療費の増加により、中国は2025年に25.05%という最大の収益シェアでアジア太平洋のブランドジェネリック医薬品市場を支配すると予想されています。
この拡大は、医療インフラに対する政府の支援の増加、慢性疾患の蔓延の増加、治療遵守に関する意識の高まりによって推進されており、これらすべてがブランドジェネリック医薬品の採用を促進しています。
インド、中国、日本、韓国などの国々は、確立された医薬品製造能力、ジェネリック医薬品に対する規制支援、国内のヘルスケア生産への投資増加により、この地域をリードしています。
さらに、現地での医薬品生産、医療へのアクセス、医薬品の輸出を促進する有利な政策により、アジア太平洋地域の市場成長がさらに加速します。

アジア太平洋地域のブランドジェネリック医薬品市場に関する洞察

アジア太平洋地域は、医療費の増加、医薬品製造の急速な工業化、慢性疾患および生活習慣病の罹患率の増加に支えられ、予測期間中にアジア太平洋地域で最も高いCAGRを記録すると予測されています。インド、中国、日本などの国々は、国内生産能力の拡大、費用対効果の高い医薬品製造、そして支援的な規制政策に牽引され、成長を牽引しています。この地域の強力な医薬品輸出能力、医療アクセスの拡大、そして現地での医薬品生産に向けた取り組みは、市場の成長をさらに加速させています。治療遵守への意識の高まりと、高品質で手頃な価格の医薬品への需要は、アジア太平洋市場におけるこの地域の優位性を引き続き強化しています。

中国アジア太平洋地域におけるブランドジェネリック医薬品市場の洞察

中国は、国内医薬品生産の促進、医療改革、そして慢性疾患負担の増加といった政府の施策に牽引され、アジア太平洋地域において最大かつ最も活力のある市場となっています。成長著しい医薬品製造インフラ、スペシャリティジェネリック医薬品の採用拡大、そして堅調な輸出ポテンシャルが市場を支えています。デジタルヘルスプラットフォームの統合と医療保険適用範囲の拡大は、中国におけるブランドジェネリック医薬品の普及をさらに促進し、中国は国内消費とアジア太平洋地域への供給の両面で重要な拠点となっています。

インド・アジア太平洋地域におけるブランドジェネリック医薬品市場の洞察

インドは、「Make in India」プログラムや医療近代化イニシアチブといった強力な政府支援を受け、ブランドジェネリック医薬品市場において最も急成長を遂げている市場の一つとして台頭しています。国内需要の増加、医薬品生産能力の拡大、そして慢性疾患罹患率の増加が、市場への導入を後押ししています。さらに、ジェネリック医薬品の輸出、ドラッグデリバリーにおけるイノベーション、そして医療インフラにおける官民連携への注力も急速な成長を促し、インドはアジア太平洋地域のブランドジェネリック医薬品市場において重要な役割を担っています。

市場で活動する主要なマーケットリーダーは次のとおりです。

テバ製薬工業株式会社（イスラエル）
Viatris Inc.（中国）
サンドスグループAG（スイス）
Dr. Reddy's Laboratories Ltd.（インド）
サン・ファーマシューティカル・インダストリーズ（インド）
オーロビンドファーマ（インド）
シプラ・ファーマシューティカルズ（インド）
フレゼニウス・カビ（ドイツ）
アボット（中国）
グレンマーク・ファーマシューティカルズ（インド）
ヒクマ・ファーマシューティカルズPLC（英国）
ルピン・ファーマシューティカルズ（インド）
エムキュア・ファーマシューティカルズ（インド）
バウシュ・ヘルス・カンパニーズ（カナダ）
マンカインドファーマ（インド）
ジュビラント・ファーマ（インド）
ナトコファーマ（インド）
アリスト・ファーマシューティカルズ・プライベート・リミテッド（インド）
バイオコン・リミテッド（インド）
トレント・ファーマシューティカルズ社（インド）
遠藤株式会社（中国）
アレンビック・ファーマシューティカルズ・リミテッド（インド）
SAGENT Pharmaceuticals（中国）
パナセアバイオテック（インド）

アジア太平洋地域のブランドジェネリック医薬品市場の最新動向

2025年10月、中国FDAはUZEDY（リスペリドン）徐放性注射懸濁液の適応拡大を承認しました。これにより、成人に加え、13歳から17歳の小児および青年の統合失調症の治療薬としても承認されました。これにより、慢性疾患を抱える若年患者にとって、長期作用型治療の選択肢が提供されます。
2025年8月、テバはSaxenda（リラグルチド）注射剤の初のジェネリック医薬品について、中国FDAの承認を取得し、発売しました。このジェネリックGLP-1受容体作動薬は、成人および小児患者の体重管理ツールとして承認されており、慢性的な体重管理のためのより利用しやすい選択肢を提供します。
2025年8月、ビアトリスは鉄欠乏性貧血の治療薬である鉄スクロース注射剤の初のジェネリック医薬品について、中国FDAの承認を取得しました。この開発により、米国の患者と医療従事者にとって、より手頃な価格の治療選択肢が提供されます。この承認により、ビアトリスのジェネリック注射剤ポートフォリオが強化され、この重要な治療への患者アクセスが向上します。
2025年4月、ビアトリスは、エフェクサー（一般名：ベンラファキシン）の全般性不安障害（GAD）治療薬として、厚生労働省に承認申請を行いました。この承認申請は、日本市場における本剤の治療用途の拡大を目的としています。承認されれば、この疾患に苦しむ日本の患者さんに新たな治療選択肢を提供することになります。

SKU-75017

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

画像をクリックすると拡大します

インタラクティブなデータ分析ダッシュボード
成長の可能性が高い機会のための企業分析ダッシュボード
カスタマイズとクエリのためのリサーチアナリストアクセス
インタラクティブなダッシュボードによる競合分析
最新ニュース、更新情報、トレンド分析
包括的な競合追跡のためのベンチマーク分析のパワーを活用

デモのリクエスト

表のリスト

TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE ASIA-PACIFIC BRANDED GENERICS MARKET

TABLE 2 PATENT LANDSCAPE

TABLE 3 ASIA-PACIFIC BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 ASIA-PACIFIC PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 76 ASIA-PACIFIC DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 78 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 ASIA-PACIFIC BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 80 ASIA-PACIFIC ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 81 ASIA-PACIFIC ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 ASIA-PACIFIC INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 83 ASIA-PACIFIC INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 ASIA-PACIFIC TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 85 ASIA-PACIFIC TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 87 ASIA-PACIFIC BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 ASIA-PACIFIC VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 89 ASIA-PACIFIC TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 90 ASIA-PACIFIC BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 91 ASIA-PACIFIC ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 92 ASIA-PACIFIC GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 93 ASIA-PACIFIC PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 94 ASIA-PACIFIC BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 95 ASIA-PACIFIC HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 96 ASIA-PACIFIC CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 97 ASIA-PACIFIC HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 98 ASIA-PACIFIC ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 99 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 100 ASIA-PACIFIC BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 101 ASIA-PACIFIC RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 102 ASIA-PACIFIC RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 ASIA-PACIFIC HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 104 ASIA-PACIFIC DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 105 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 106 ASIA-PACIFIC BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 107 ASIA-PACIFIC BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 108 ASIA-PACIFIC ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 ASIA-PACIFIC DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 ASIA-PACIFIC ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 ASIA-PACIFIC ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 ASIA-PACIFIC BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 ASIA-PACIFIC CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 ASIA-PACIFIC DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 ASIA-PACIFIC ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 ASIA-PACIFIC CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 ASIA-PACIFIC HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 ASIA-PACIFIC STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 ASIA-PACIFIC SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 ASIA-PACIFIC ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 ASIA-PACIFIC PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 ASIA-PACIFIC ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 ASIA-PACIFIC THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 ASIA-PACIFIC OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 ASIA-PACIFIC ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 ASIA-PACIFIC PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 ASIA-PACIFIC PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 ASIA-PACIFIC FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 ASIA-PACIFIC LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 ASIA-PACIFIC STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 ASIA-PACIFIC COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 ASIA-PACIFIC FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 ASIA-PACIFIC PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 ASIA-PACIFIC ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 ASIA-PACIFIC ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 ASIA-PACIFIC NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 ASIA-PACIFIC NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 ASIA-PACIFIC ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 ASIA-PACIFIC TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 ASIA-PACIFIC ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 ASIA-PACIFIC ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 ASIA-PACIFIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 ASIA-PACIFIC SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 ASIA-PACIFIC TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 ASIA-PACIFIC ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 ASIA-PACIFIC MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 ASIA-PACIFIC NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 ASIA-PACIFIC ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 ASIA-PACIFIC SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 ASIA-PACIFIC FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 ASIA-PACIFIC PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 ASIA-PACIFIC THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 ASIA-PACIFIC NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 ASIA-PACIFIC BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 156 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 ASIA-PACIFIC PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 ASIA-PACIFIC ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 ASIA-PACIFIC SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 ASIA-PACIFIC DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 ASIA-PACIFIC NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 ASIA-PACIFIC GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 ASIA-PACIFIC DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 ASIA-PACIFIC OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 ASIA-PACIFIC BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 167 ASIA-PACIFIC ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 ASIA-PACIFIC INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 ASIA-PACIFIC TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 ASIA-PACIFIC BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 ASIA-PACIFIC BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 172 ASIA-PACIFIC BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 173 ASIA-PACIFIC BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 ASIA-PACIFIC RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 CHINA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 176 CHINA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 CHINA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 CHINA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 CHINA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 CHINA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 CHINA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 CHINA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 CHINA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 CHINA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 CHINA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 CHINA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 CHINA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 CHINA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 CHINA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 CHINA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 CHINA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 CHINA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 CHINA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 CHINA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 CHINA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 CHINA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 CHINA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 CHINA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 CHINA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 CHINA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 CHINA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 CHINA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 CHINA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 CHINA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 CHINA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 CHINA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 CHINA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 CHINA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 CHINA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 CHINA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 CHINA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 CHINA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 CHINA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 CHINA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 CHINA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 CHINA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 CHINA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 CHINA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 CHINA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 CHINA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 CHINA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 CHINA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 CHINA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 224 CHINA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 CHINA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 CHINA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 CHINA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 CHINA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 CHINA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 CHINA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 CHINA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 CHINA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 CHINA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 CHINA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 235 CHINA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 236 CHINA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 CHINA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 CHINA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 CHINA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 240 CHINA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 241 CHINA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 242 CHINA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 INDIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 244 INDIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 INDIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 INDIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 INDIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 INDIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 INDIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 INDIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 INDIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 INDIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 INDIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 INDIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 INDIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 INDIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 INDIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 INDIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 INDIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 INDIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 INDIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 INDIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 INDIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 INDIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 INDIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 INDIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 INDIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 INDIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 INDIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 INDIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 INDIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 INDIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 INDIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 INDIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 INDIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 INDIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 INDIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 INDIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 INDIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 INDIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 INDIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 INDIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 INDIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 INDIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 INDIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 INDIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 INDIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 INDIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 INDIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 INDIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 INDIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 292 INDIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 INDIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 INDIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 INDIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 INDIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 INDIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 INDIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 INDIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 INDIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 INDIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 INDIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 INDIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 INDIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 INDIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 INDIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 INDIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 308 INDIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 309 INDIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 310 INDIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 JAPAN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 312 JAPAN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 313 JAPAN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 JAPAN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 JAPAN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 JAPAN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 JAPAN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 JAPAN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 JAPAN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 JAPAN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 JAPAN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 JAPAN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 JAPAN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 JAPAN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 JAPAN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 JAPAN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 JAPAN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 JAPAN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 JAPAN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 JAPAN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 JAPAN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 JAPAN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 JAPAN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 JAPAN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 JAPAN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 JAPAN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 JAPAN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 JAPAN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 JAPAN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 JAPAN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 JAPAN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 JAPAN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 JAPAN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 JAPAN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 JAPAN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 JAPAN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 JAPAN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 JAPAN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 JAPAN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 JAPAN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 JAPAN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 JAPAN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 JAPAN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 JAPAN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 JAPAN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 JAPAN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 JAPAN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 JAPAN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 JAPAN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 360 JAPAN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 JAPAN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 JAPAN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 JAPAN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 JAPAN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 JAPAN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 JAPAN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 JAPAN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 JAPAN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 JAPAN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 JAPAN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 371 JAPAN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 JAPAN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 JAPAN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 JAPAN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 JAPAN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 376 JAPAN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 377 JAPAN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 378 JAPAN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 SOUTH KOREA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 380 SOUTH KOREA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 SOUTH KOREA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 SOUTH KOREA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 SOUTH KOREA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 SOUTH KOREA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 SOUTH KOREA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 SOUTH KOREA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 SOUTH KOREA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 SOUTH KOREA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 SOUTH KOREA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 SOUTH KOREA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 391 SOUTH KOREA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 392 SOUTH KOREA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SOUTH KOREA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 394 SOUTH KOREA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 SOUTH KOREA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 SOUTH KOREA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 SOUTH KOREA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 SOUTH KOREA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 SOUTH KOREA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 SOUTH KOREA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SOUTH KOREA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 SOUTH KOREA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 SOUTH KOREA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 SOUTH KOREA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 SOUTH KOREA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 SOUTH KOREA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 SOUTH KOREA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 SOUTH KOREA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 SOUTH KOREA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 SOUTH KOREA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 SOUTH KOREA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 SOUTH KOREA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 413 SOUTH KOREA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 SOUTH KOREA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 SOUTH KOREA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 SOUTH KOREA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 SOUTH KOREA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 SOUTH KOREA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 SOUTH KOREA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 SOUTH KOREA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 421 SOUTH KOREA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 SOUTH KOREA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 SOUTH KOREA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 SOUTH KOREA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 SOUTH KOREA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 SOUTH KOREA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 SOUTH KOREA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 428 SOUTH KOREA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 SOUTH KOREA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 SOUTH KOREA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 SOUTH KOREA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 SOUTH KOREA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 433 SOUTH KOREA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 434 SOUTH KOREA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 SOUTH KOREA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 436 SOUTH KOREA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 SOUTH KOREA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 438 SOUTH KOREA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 439 SOUTH KOREA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 SOUTH KOREA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 441 SOUTH KOREA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 442 SOUTH KOREA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 SOUTH KOREA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 444 SOUTH KOREA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 445 SOUTH KOREA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 446 SOUTH KOREA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 AUSTRALIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 448 AUSTRALIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 AUSTRALIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 AUSTRALIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 AUSTRALIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 AUSTRALIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 AUSTRALIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 AUSTRALIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 AUSTRALIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 AUSTRALIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 AUSTRALIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 AUSTRALIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 AUSTRALIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 AUSTRALIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 AUSTRALIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 AUSTRALIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 463 AUSTRALIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 464 AUSTRALIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 AUSTRALIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 AUSTRALIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 AUSTRALIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 468 AUSTRALIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 AUSTRALIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 AUSTRALIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 471 AUSTRALIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 AUSTRALIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 AUSTRALIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 474 AUSTRALIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 AUSTRALIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 AUSTRALIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 AUSTRALIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 AUSTRALIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 AUSTRALIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 480 AUSTRALIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 481 AUSTRALIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 AUSTRALIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 483 AUSTRALIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 AUSTRALIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 AUSTRALIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 486 AUSTRALIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 AUSTRALIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 488 AUSTRALIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 489 AUSTRALIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 AUSTRALIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 491 AUSTRALIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 492 AUSTRALIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 AUSTRALIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 494 AUSTRALIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 495 AUSTRALIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 496 AUSTRALIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 497 AUSTRALIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 498 AUSTRALIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 499 AUSTRALIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 AUSTRALIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 AUSTRALIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 AUSTRALIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 503 AUSTRALIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 AUSTRALIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 AUSTRALIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 AUSTRALIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 507 AUSTRALIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 AUSTRALIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 AUSTRALIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 AUSTRALIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 AUSTRALIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 512 AUSTRALIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 513 AUSTRALIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 514 AUSTRALIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 THAILAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 516 THAILAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 THAILAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 518 THAILAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 THAILAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 THAILAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 521 THAILAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 THAILAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 THAILAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 524 THAILAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 THAILAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 THAILAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 527 THAILAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 528 THAILAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 THAILAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 530 THAILAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 531 THAILAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 THAILAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 533 THAILAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 534 THAILAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 THAILAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 536 THAILAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 THAILAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 538 THAILAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 539 THAILAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 THAILAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 541 THAILAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 542 THAILAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 THAILAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 544 THAILAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 545 THAILAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 THAILAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 547 THAILAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 548 THAILAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 549 THAILAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 THAILAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 THAILAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 THAILAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 553 THAILAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 THAILAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 THAILAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 THAILAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 THAILAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 THAILAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 THAILAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 THAILAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 THAILAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 562 THAILAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 563 THAILAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 564 THAILAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 THAILAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 THAILAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 THAILAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 568 THAILAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 569 THAILAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 570 THAILAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 571 THAILAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 THAILAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 THAILAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 574 THAILAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 575 THAILAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 576 THAILAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 THAILAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 578 THAILAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 579 THAILAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 580 THAILAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 581 THAILAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 582 THAILAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 583 INDONESIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 584 INDONESIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 585 INDONESIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 586 INDONESIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 INDONESIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 588 INDONESIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 589 INDONESIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 INDONESIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 591 INDONESIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 592 INDONESIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 INDONESIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 594 INDONESIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 595 INDONESIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 INDONESIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 597 INDONESIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 598 INDONESIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 599 INDONESIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 600 INDONESIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 INDONESIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 INDONESIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 603 INDONESIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 INDONESIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 605 INDONESIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 INDONESIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 INDONESIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 INDONESIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 INDONESIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 INDONESIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 INDONESIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 INDONESIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 613 INDONESIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 614 INDONESIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 INDONESIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 INDONESIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 INDONESIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 618 INDONESIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 INDONESIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 620 INDONESIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 621 INDONESIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 INDONESIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 INDONESIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 624 INDONESIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 INDONESIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 INDONESIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 627 INDONESIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 628 INDONESIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 INDONESIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 630 INDONESIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 631 INDONESIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 632 INDONESIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 633 INDONESIA PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 634 INDONESIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 INDONESIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 636 INDONESIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 INDONESIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 638 INDONESIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 639 INDONESIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 INDONESIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 641 INDONESIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 642 INDONESIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 643 INDONESIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 644 INDONESIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 645 INDONESIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 INDONESIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 647 INDONESIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 648 INDONESIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 649 INDONESIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 650 INDONESIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 651 SINGAPORE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 652 SINGAPORE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 653 SINGAPORE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 654 SINGAPORE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 655 SINGAPORE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 656 SINGAPORE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 657 SINGAPORE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 SINGAPORE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 SINGAPORE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 SINGAPORE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 661 SINGAPORE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 662 SINGAPORE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 663 SINGAPORE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 664 SINGAPORE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 SINGAPORE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 666 SINGAPORE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 667 SINGAPORE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 668 SINGAPORE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 669 SINGAPORE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 670 SINGAPORE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 671 SINGAPORE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 672 SINGAPORE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 673 SINGAPORE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 674 SINGAPORE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 675 SINGAPORE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 676 SINGAPORE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 677 SINGAPORE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 678 SINGAPORE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 679 SINGAPORE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 680 SINGAPORE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 681 SINGAPORE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 682 SINGAPORE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 683 SINGAPORE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 684 SINGAPORE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 685 SINGAPORE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 686 SINGAPORE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 SINGAPORE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 688 SINGAPORE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 689 SINGAPORE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 690 SINGAPORE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 691 SINGAPORE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 692 SINGAPORE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 SINGAPORE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 694 SINGAPORE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 695 SINGAPORE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 696 SINGAPORE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 697 SINGAPORE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 698 SINGAPORE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 699 SINGAPORE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 700 SINGAPORE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 701 SINGAPORE PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 702 SINGAPORE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 703 SINGAPORE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 704 SINGAPORE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 705 SINGAPORE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 706 SINGAPORE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 707 SINGAPORE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 708 SINGAPORE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 709 SINGAPORE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 710 SINGAPORE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 711 SINGAPORE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 SINGAPORE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 713 SINGAPORE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 714 SINGAPORE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 715 SINGAPORE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 716 SINGAPORE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 717 SINGAPORE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 718 SINGAPORE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 MALAYSIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 720 MALAYSIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 721 MALAYSIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 722 MALAYSIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 723 MALAYSIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 724 MALAYSIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 MALAYSIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 726 MALAYSIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 727 MALAYSIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 728 MALAYSIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 729 MALAYSIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 730 MALAYSIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 731 MALAYSIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 732 MALAYSIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 733 MALAYSIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 734 MALAYSIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 735 MALAYSIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 736 MALAYSIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 737 MALAYSIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 738 MALAYSIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 739 MALAYSIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 MALAYSIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 741 MALAYSIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 742 MALAYSIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 743 MALAYSIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 744 MALAYSIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 745 MALAYSIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 746 MALAYSIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 747 MALAYSIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 748 MALAYSIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 749 MALAYSIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 750 MALAYSIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 MALAYSIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 752 MALAYSIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 753 MALAYSIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 754 MALAYSIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 755 MALAYSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 756 MALAYSIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 757 MALAYSIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 758 MALAYSIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 759 MALAYSIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 760 MALAYSIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 761 MALAYSIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 762 MALAYSIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 763 MALAYSIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 764 MALAYSIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 765 MALAYSIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 MALAYSIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 MALAYSIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 768 MALAYSIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 769 MALAYSIA PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 770 MALAYSIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 771 MALAYSIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 MALAYSIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 MALAYSIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 774 MALAYSIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 775 MALAYSIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 776 MALAYSIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 777 MALAYSIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 778 MALAYSIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 779 MALAYSIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 780 MALAYSIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 781 MALAYSIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 782 MALAYSIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 783 MALAYSIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 784 MALAYSIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 785 MALAYSIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 786 MALAYSIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 787 TAIWAN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 788 TAIWAN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 789 TAIWAN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 790 TAIWAN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 791 TAIWAN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 792 TAIWAN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 793 TAIWAN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 794 TAIWAN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 795 TAIWAN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 796 TAIWAN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 797 TAIWAN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 798 TAIWAN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 799 TAIWAN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 800 TAIWAN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 801 TAIWAN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 802 TAIWAN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 803 TAIWAN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 804 TAIWAN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 805 TAIWAN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 806 TAIWAN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 807 TAIWAN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 808 TAIWAN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 809 TAIWAN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 810 TAIWAN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 811 TAIWAN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 812 TAIWAN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 813 TAIWAN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 814 TAIWAN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 815 TAIWAN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 816 TAIWAN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 817 TAIWAN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 818 TAIWAN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 819 TAIWAN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 820 TAIWAN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 821 TAIWAN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 822 TAIWAN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 823 TAIWAN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 824 TAIWAN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 825 TAIWAN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 826 TAIWAN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 827 TAIWAN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 828 TAIWAN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 829 TAIWAN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 830 TAIWAN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 831 TAIWAN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 832 TAIWAN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 833 TAIWAN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 834 TAIWAN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 835 TAIWAN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 836 TAIWAN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 837 TAIWAN PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 838 TAIWAN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 839 TAIWAN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 840 TAIWAN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 841 TAIWAN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 842 TAIWAN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 843 TAIWAN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 844 TAIWAN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 845 TAIWAN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 846 TAIWAN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 847 TAIWAN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 848 TAIWAN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 849 TAIWAN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 850 TAIWAN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 851 TAIWAN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 852 TAIWAN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 853 TAIWAN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 854 TAIWAN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 855 PHILIPPINES BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 856 PHILIPPINES ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 857 PHILIPPINES DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 858 PHILIPPINES ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 859 PHILIPPINES ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 860 PHILIPPINES BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 861 PHILIPPINES CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 862 PHILIPPINES DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 863 PHILIPPINES ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 864 PHILIPPINES CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 865 PHILIPPINES HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 866 PHILIPPINES STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 867 PHILIPPINES SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 868 PHILIPPINES ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 869 PHILIPPINES PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 870 PHILIPPINES ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 871 PHILIPPINES THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 872 PHILIPPINES OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 873 PHILIPPINES ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 874 PHILIPPINES PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 875 PHILIPPINES PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 876 PHILIPPINES FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 877 PHILIPPINES LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 878 PHILIPPINES STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 879 PHILIPPINES COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 880 PHILIPPINES FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 881 PHILIPPINES BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 882 PHILIPPINES PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 883 PHILIPPINES ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 884 PHILIPPINES ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 885 PHILIPPINES NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 886 PHILIPPINES NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 887 PHILIPPINES ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 888 PHILIPPINES TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 889 PHILIPPINES ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 890 PHILIPPINES ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 891 PHILIPPINES SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 892 PHILIPPINES SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 893 PHILIPPINES TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 894 PHILIPPINES ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 895 PHILIPPINES MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 896 PHILIPPINES NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 897 PHILIPPINES ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 898 PHILIPPINES SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 899 PHILIPPINES FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 900 PHILIPPINES PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 901 PHILIPPINES THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 902 PHILIPPINES NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 903 PHILIPPINES BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 904 PHILIPPINES CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 905 PHILIPPINES PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 906 PHILIPPINES ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 907 PHILIPPINES SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 908 PHILIPPINES HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 909 PHILIPPINES DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 910 PHILIPPINES NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 911 PHILIPPINES GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 912 PHILIPPINES DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 913 PHILIPPINES OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 914 PHILIPPINES BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 915 PHILIPPINES ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 916 PHILIPPINES INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 917 PHILIPPINES TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 918 PHILIPPINES BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 919 PHILIPPINES BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 920 PHILIPPINES BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 921 PHILIPPINES BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 922 PHILIPPINES RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 923 HONG KONG BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 924 HONG KONG ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 925 HONG KONG DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 926 HONG KONG ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 927 HONG KONG ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 928 HONG KONG BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 929 HONG KONG CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 930 HONG KONG DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 931 HONG KONG ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 932 HONG KONG CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 933 HONG KONG HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 934 HONG KONG STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 935 HONG KONG SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 936 HONG KONG ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 937 HONG KONG PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 938 HONG KONG ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 939 HONG KONG THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 940 HONG KONG OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 941 HONG KONG ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 942 HONG KONG PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 943 HONG KONG PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 944 HONG KONG FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 945 HONG KONG LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 946 HONG KONG STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 947 HONG KONG COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 948 HONG KONG FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 949 HONG KONG BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 950 HONG KONG PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 951 HONG KONG ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 952 HONG KONG ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 953 HONG KONG NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 954 HONG KONG NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 955 HONG KONG ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 956 HONG KONG TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 957 HONG KONG ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 958 HONG KONG ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 959 HONG KONG SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 960 HONG KONG SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 961 HONG KONG TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 962 HONG KONG ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 963 HONG KONG MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 964 HONG KONG NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 965 HONG KONG ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 966 HONG KONG SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 967 HONG KONG FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 968 HONG KONG PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 969 HONG KONG THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 970 HONG KONG NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 971 HONG KONG BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 972 HONG KONG CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 973 HONG KONG PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 974 HONG KONG ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 975 HONG KONG SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 976 HONG KONG HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 977 HONG KONG DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 978 HONG KONG NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 979 HONG KONG GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 980 HONG KONG DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 981 HONG KONG OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 982 HONG KONG BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 983 HONG KONG ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 984 HONG KONG INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 985 HONG KONG TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 986 HONG KONG BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 987 HONG KONG BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 988 HONG KONG BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 989 HONG KONG BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 990 HONG KONG RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 991 NEW ZEALAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 992 NEW ZEALAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 993 NEW ZEALAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 994 NEW ZEALAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 995 NEW ZEALAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 996 NEW ZEALAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 997 NEW ZEALAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 998 NEW ZEALAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 999 NEW ZEALAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1000 NEW ZEALAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1001 NEW ZEALAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1002 NEW ZEALAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1003 NEW ZEALAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1004 NEW ZEALAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1005 NEW ZEALAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1006 NEW ZEALAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1007 NEW ZEALAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1008 NEW ZEALAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1009 NEW ZEALAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1010 NEW ZEALAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1011 NEW ZEALAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1012 NEW ZEALAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1013 NEW ZEALAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1014 NEW ZEALAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1015 NEW ZEALAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1016 NEW ZEALAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1017 NEW ZEALAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1018 NEW ZEALAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1019 NEW ZEALAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1020 NEW ZEALAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1021 NEW ZEALAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1022 NEW ZEALAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1023 NEW ZEALAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1024 NEW ZEALAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1025 NEW ZEALAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1026 NEW ZEALAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1027 NEW ZEALAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1028 NEW ZEALAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1029 NEW ZEALAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1030 NEW ZEALAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1031 NEW ZEALAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1032 NEW ZEALAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1033 NEW ZEALAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1034 NEW ZEALAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1035 NEW ZEALAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1036 NEW ZEALAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1037 NEW ZEALAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1038 NEW ZEALAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1039 NEW ZEALAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 1040 NEW ZEALAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1041 NEW ZEALAND PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1042 NEW ZEALAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1043 NEW ZEALAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1044 NEW ZEALAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1045 NEW ZEALAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1046 NEW ZEALAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1047 NEW ZEALAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1048 NEW ZEALAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1049 NEW ZEALAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1050 NEW ZEALAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 1051 NEW ZEALAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1052 NEW ZEALAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1053 NEW ZEALAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1054 NEW ZEALAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 1055 NEW ZEALAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 1056 NEW ZEALAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 1057 NEW ZEALAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 1058 NEW ZEALAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 1059 REST OF ASIA-PACIFIC BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

図表一覧

FIGURE 1 ASIA-PACIFIC BRANDED GENERICS MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC BRANDED GENERICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC BRANDED GENERICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC BRANDED GENERICS MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS

FIGURE 5 ASIA-PACIFIC BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EXECUTIVE SUMMARY

FIGURE 10 STRATEGIC DECISIONS

FIGURE 11 NINE SEGMENTS COMPRISE THE ASIA-PACIFIC BRANDED GENERICS MARKET, BY DRUG CLASS (2024)

FIGURE 12 ASIA-PACIFIC BRANDED GENERICS MARKET: SEGMENTATION

FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE ASIA-PACIFIC BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC BRANDED GENERICS MARKET IN 2025 & 2032

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA-PACIFIC BRANDED GENERICS MARKET

FIGURE 16 ASIA-PACIFIC BRANDED GENERIC MARKET: BY DRUG CLASS, 2024

FIGURE 17 ASIA-PACIFIC BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)

FIGURE 18 ASIA-PACIFIC BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)

FIGURE 19 ASIA-PACIFIC BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 20 ASIA-PACIFIC BRANDED GENERICS MARKET: BY APPLICATION, 2024

FIGURE 21 ASIA-PACIFIC BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 22 ASIA-PACIFIC BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)

FIGURE 23 ASIA-PACIFIC BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 24 ASIA-PACIFIC BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 25 ASIA-PACIFIC BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 26 ASIA-PACIFIC BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)

FIGURE 27 ASIA-PACIFIC BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024

FIGURE 29 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)

FIGURE 30 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)

FIGURE 31 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024

FIGURE 33 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)

FIGURE 34 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)

FIGURE 35 ASIA-PACIFIC BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE

FIGURE 36 ASIA-PACIFIC BRANDED GENERICS MARKET: BY END USER, 2024

FIGURE 37 ASIA-PACIFIC BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)

FIGURE 38 ASIA-PACIFIC BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)

FIGURE 39 ASIA-PACIFIC BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 ASIA-PACIFIC BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 41 ASIA-PACIFIC BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)

FIGURE 42 ASIA-PACIFIC BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)

FIGURE 43 ASIA-PACIFIC BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 ASIA-PACIFIC BRANDED GENERICS MARKET: SNAPSHOT (2024)

FIGURE 45 ASIA-PACIFIC BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)

詳細情報を見る

調査方法

データ収集と基準年分析は、大規模なサンプルサイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データマイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データモデルには、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダーシェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータスタイルでいくつでも追加できます。当社のアナリストチームは、粗い生の Excel ファイルピボットテーブル (ファクトブック) でデータを提供したり、レポートで利用可能なデータセットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

アジア太平洋地域におけるブランドジェネリック医薬品市場のレポートに含まれる主なセグメントは何ですか？

市場はアジア太平洋地域におけるブランドジェネリック医薬品市場の細分化：薬物クラス別（降圧剤、ホルモン剤、代謝拮抗剤、脂質低下薬、抗てんかん剤、アルキル化剤、抗うつ剤、抗精神病薬、その他）、用途別（心血管疾患、疼痛管理・抗炎症剤、腫瘍学、糖尿病、神経学、消化器疾患、皮膚科、その他）、投与経路別（経口、注射、局所投与、その他）、製品タイプ別（付加価値ブランドジェネリック医薬品、商品名ジェネリック医薬品）、患者層別（成人、高齢者、小児）、エンドユーザー別（病院、診療所、在宅ケア、学術研究機関、その他）、流通チャネル別（小売薬局、病院薬局、直接販売、その他） - 2032年までの業界動向と予測に基づいて分類されます。

アジア太平洋地域におけるブランドジェネリック医薬品市場の現在の市場規模は？

アジア太平洋地域におけるブランドジェネリック医薬品市場の規模は2024年にUSD 95.35 USD Billionと推定されました。

アジア太平洋地域におけるブランドジェネリック医薬品市場の予測成長率は？

アジア太平洋地域におけるブランドジェネリック医薬品市場は2025年から2032年の予測期間にCAGR 4.8%で成長すると見込まれています。

アジア太平洋地域におけるブランドジェネリック医薬品市場の主要プレーヤーは？

市場で活動している主要プレーヤーはTeva Pharmaceutical Industries Ltd. ,Viatris Inc. ,Sandoz Group AG ,Dr. Reddy’s Laboratories Ltd. ,Sun Pharmaceutical Industries Ltd.です。

アジア太平洋地域におけるブランドジェネリック医薬品市場の規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

アジア太平洋地域におけるブランドジェネリック医薬品市場の規模、シェア、トレンド分析レポート

CAGR : 4.80 %

アジア太平洋地域のブランドジェネリック医薬品市場規模

アジア太平洋地域のブランドジェネリック医薬品市場分析

レポートの範囲とアジア太平洋地域のブランドジェネリック医薬品市場のセグメンテーション

アジア太平洋地域のブランドジェネリック医薬品主要市場インサイト

アジア太平洋地域のブランドジェネリック医薬品市場動向

アジア太平洋地域のブランドジェネリック医薬品市場の動向

アジア太平洋地域のブランドジェネリック医薬品市場の展望

アジア太平洋地域のブランドジェネリック医薬品市場 – 地域分析

アジア太平洋地域のブランドジェネリック医薬品市場の最新動向

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

Frequently Asked Questions

ISO認証

レポート

市場洞察

サポート

ソリューション

アジア太平洋地域におけるブランドジェネリック医薬品市場の規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

アジア太平洋地域におけるブランドジェネリック医薬品市場の規模、シェア、トレンド分析レポート

CAGR : 4.80 %

アジア太平洋地域のブランドジェネリック医薬品市場規模

アジア太平洋地域のブランドジェネリック医薬品市場分析

レポートの範囲とアジア太平洋地域のブランドジェネリック医薬品市場のセグメンテーション

アジア太平洋地域のブランドジェネリック医薬品主要市場インサイト

アジア太平洋地域のブランドジェネリック医薬品市場動向

アジア太平洋地域のブランドジェネリック医薬品市場の動向

アジア太平洋地域のブランドジェネリック医薬品市場の展望

アジア太平洋地域のブランドジェネリック医薬品市場 – 地域分析

アジア太平洋地域のブランドジェネリック医薬品市場の最新動向

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

Frequently Asked Questions

関連ページを閲覧する